How to Help Your Patients Find Entrectinib in Stock: A Provider's Guide

When you prescribe Entrectinib (Rozlytrek) for a patient with ROS1-positive NSCLC or NTRK fusion-positive solid tumors, getting the prescription filled is rarely straightforward. As an oncology provider, your team plays a pivotal role in bridging the gap between the prescription and the patient's first dose. This guide outlines the most effective steps you can take to help your patients access Rozlytrek quickly and without interruption.

Step 1: Initiate Genentech Access Solutions at the Time of Prescription

The single most effective action you can take is to engage Genentech Access Solutions (877-436-3683, Monday–Friday 6am–5pm PT) at the same time you write the prescription. Don't wait for the patient to encounter a problem. Submit both the Prescriber Service Form and Patient Consent Form upfront. Access Solutions will then:

Conduct a benefits investigation to identify coverage status, specialty pharmacy routing, and prior authorization requirements

Flag patients who may need financial assistance and connect them with the appropriate program

Assign a Field Reimbursement Manager (FRM) who can help navigate complex coverage situations or PA denials

Step 2: Ensure Biomarker Documentation Is Ready

Nearly every payer requires an FDA-approved biomarker test result as part of the prior authorization. Without this documentation, PA submissions will be delayed or denied. Make sure the following are in the patient's chart and ready to include with any PA submission:

Full laboratory report from the FDA-approved molecular test (e.g., next-generation sequencing panel, FISH, or RT-PCR) confirming ROS1 rearrangement or NTRK gene fusion

Confirmation that no known acquired resistance mutation is present (for NTRK indication)

Staging documentation confirming metastatic disease or surgical morbidity rationale

Documentation of prior systemic therapy (for NTRK indication where prior treatment is required)

Step 3: Use Your Pharmacy Liaison or Case Manager

If your practice has a pharmacy liaison, oncology nurse navigator, or case manager, route entrectinib prescriptions through them from day one. These professionals know your institution's specialty pharmacy contracts, have relationships with payer PA teams, and can often accelerate the process by days. If you're a smaller practice without dedicated staff, Genentech's FRM network can fill this gap.

Step 4: Know the Most Common Causes of Access Failure — and How to Preempt Them

PA denial due to missing biomarker documentation: Always attach the full test report, not just a clinical note summarizing the result.

Specialty pharmacy not in network: Verify the patient's insurer-preferred specialty pharmacy before routing. Sending to the wrong pharmacy adds days.

PA renewal lapse: Most PAs are good for 12 months. Set a calendar alert 60 days before expiration and initiate renewal paperwork proactively.

Insurance plan change at year-end: Confirm coverage status at the start of each calendar year for all patients on Rozlytrek.

Step 5: Know the Appeal Process

If a PA is denied, submit a written appeal with supporting clinical documentation immediately. Genentech Access Solutions provides a sample appeal letter that you can adapt. Include:

Your clinical rationale for entrectinib over alternatives, citing NCCN guidelines and published trial data

The complete biomarker test result

Peer-reviewed literature supporting entrectinib for the specific indication

A statement on medical urgency if the patient is at risk of disease progression from the delay

How medfinder Can Support Your Patients

When your patients are struggling to identify which specialty pharmacy in their area can fill their Rozlytrek prescription, medfinder contacts pharmacies on their behalf and texts them the results. This is particularly useful for patients in rural or underserved areas where specialty pharmacy access is limited. For more on current entrectinib availability, see our provider shortage guide.